Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Not yet recruiting 2Withdrawn 1Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 1Recurrence 1Polycystic Ovary Syndrome 1Infertility, Female 1Hypothyroidism 1

Interventions

Magnetic Resonance Spectroscopy 4Surgical Procedures, Operative 3Iodine-131 3Iodine-124 3Biopsy 3selpercatinib 2lenvatinib 2Watchful Waiting 2Thyrotropin Alfa 2Therapeutics 2Nivolumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Cetuximab 2Biopsy, Fine-Needle 2trastuzumab deruxtecan 1trametinib 1sintilimab 1sacituzumab govitecan 1repotrectinib 1pralsetinib 1pembrolizumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1defactinib 1dabrafenib 1cemiplimab 1brodalumab 1binimetinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Thyroid Neoplasms × Thyroxine × Clear all
NCT06087068 2023-10-17

Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
140 enrolled
Head & Neck

Recurrence, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡